2
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Did telemedicine come to stay in children's neurology?

      editorial
      Iberoamerican Journal of Medicine
      Hospital San Pedro
      Telemedicine, COVID-19, Children, Pediatrics, Neurology

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Most cited references5

          • Record: found
          • Abstract: found
          • Article: not found

          The response of the mental health network of the Salamanca area to the COVID-19 pandemic: The role of the telemedicine.

          Highlights • The COVID-19 pandemic has spread causing a great impact on healthcare services. • The response of the Mental Health Network of the Salamanca area to the infection of the COVID-19. The implementation plan of our Mental Health Network to this crisis in the Salamanca area (Spain) and the reorganization of its resources within the first 8 weeks after the state of alarm was described. • This response includes the reorganization of the human resources, the units, and the implementation of massive tele-medicine programs, with more than 9000 contact. • Two specific programs were implementing the first one for preventing and treating mental disorders for patient and relatives and health and the second for homeless people.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Supporting children with autism spectrum disorder in the face of the COVID-19 pandemic

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Starting ADHD medications during the COVID-19 pandemic: recommendations from the European ADHD Guidelines Group

              This addendum to our previous Comment 1 provides additional guidance from the European ADHD Guidelines Group (EAGG) on starting attention-deficit hyperactivity disorder (ADHD) medications (specifically psychostimulants and atomoxetine), during the coronavirus disease 2019 (COVID-19) pandemic, for patients who did not have a baseline, face-to-face cardiovascular assessment before the crisis began. The EAGG deems it appropriate, in terms of the risk–benefit ratio, to remotely start a pharmacological treatment if the three following conditions are satisfied. First, the individual with ADHD should not have a personal history of shortness of breath on exertion compared with peers; fainting on exertion or in response to fright or noise; excessive palpitations, breathlessness or syncope (at rest or after exercise) or palpitations that are rapid, regular, and start and stop suddenly (fleeting occasional bumps are usually ectopic and do not need investigation); chest pain suggesting cardiac origin; or any previously documented hypertension, congenital heart abnormality, previous cardiac surgery, or underlying condition that increases the risk of having a structural cardiac disorder (eg, genetic conditions or multisystemic disorders). 2 The second condition is that the individual with ADHD does not have a family history of early (<40 years) sudden death in a first-degree relative suggesting cardiac disease. Finally, the patient must have baseline monitoring before initiation; blood pressure and heart rate can be measured by a family member or another person remotely (with telephonic assistance, if needed) on three separate occasions (details are provided in the appendix of our previous Comment 1 ). If the first or second conditions are not satisfied, a referral to a cardiologist should be made before starting the pharmacological treatment. If only the third condition (baseline monitoring) is not satisfied, the prescriber will need to evaluate the risks and benefits of a face-to-face assessment in the context of the severity of ADHD symptoms, and the impact on the patient and the family. As detailed in our previous 2013 guidance, 3 if persistent tachycardia or a history suggestive of arrhythmia or familial risk is identified, it is appropriate to request a 24-h electrocardiogram (ECG), rather than a standard, 12-lead ECG. The EAGG considers that, given the current circumstances, in the absence of risk factors described in the first and second conditions, a cardiac auscultation should not be mandatory before starting a medication for ADHD.
                Bookmark

                Author and article information

                Journal
                ijm
                Iberoamerican Journal of Medicine
                Iberoam J Med
                Hospital San Pedro (Logroño, La Rioja, Spain )
                2695-5075
                2695-5075
                2021
                : 3
                : 2
                : 100-101
                Affiliations
                [1] Logroño orgnameHospital San Pedro orgdiv1Pediatric Neurology Unit, Department of Pediatrics España
                Article
                S2695-50752021000200001 S2695-5075(21)00300200001
                10.5281/zenodo.4661115
                72d94149-39f6-4cdb-995f-0bfb327727e2

                This work is licensed under a Creative Commons Attribution 4.0 International License.

                History
                : 03 April 2021
                : 31 March 2021
                Page count
                Figures: 0, Tables: 0, Equations: 0, References: 5, Pages: 2
                Product

                SciELO Spain

                Categories
                Editorial

                COVID-19,Children,Pediatrics,Neurology,Telemedicine
                COVID-19, Children, Pediatrics, Neurology, Telemedicine

                Comments

                Comment on this article